 Even though elective procedures are returning to the pre-pandemic level, the rise of the Omicron variant resurgence may continue to impact the case volume in the upcoming quarters. ClearPoint Neuro is working with 40 biology partners as of Q321, and with 100 potential partners in the intracranial and spine segment, this increases the odds of multiple commercialization. 